Mini ReviewOpen Access

Angiogenesis Inhibitors for Cancer Therapy

Volume 2 - Issue 5

Mehdi Rajabi and Shaker A Mousa*

Author Information Open or Close
- Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, USA
*Corresponding author: Shaker A Mousa, The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Discovery Drive, Rensselaer, New York, USA

Received: February 21, 2018; Published: March 01, 2018

DOI: 10.26717/BJSTR.2018.02.000814

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Inhibition of angiogenesis, which refers to blocking the vessel formation from pre-existing blood vessels, has become an attractive target for cancer therapy. Tumors beyond 2-3 mm in size induce the sprouting of new blood vessels from the surrounding vasculature (sprouting angiogenesis). Design and development of new angiogenesis inhibitors has been validated as a target in several tumor types. In this min-review, we will focus on the role of different anti-angiogenesis strategies and inhibitors in treatment of cancer.

Keywords: VEGF: Vascular Endothelial Growth Factor; TGF: Transforming Growth Factor; TNF: Tumor Necrosis Factor; bFGF: Basic Fibroblast Growth Factor; PLGA: Poly Lactic-Co-Glycolic Acid

Abstract| Introduction| Conclusion| References|